| (a) Humans.
(1) Identification of notifiable conditions.
(A) A summary list of notifiable conditions and reporting
time frames is published on the Department of State Health Services
web site at http://www.dshs.state.tx.us/idcu/. Copies are filed in
the Emerging and Acute Infectious Disease Branch, Department of State
Health Services, 1100 West 49th Street, Austin, Texas 78756.
(B) Repetitive test results from the same patient do
not need to be reported except those for mycobacterial infections.
(2) Notifiable conditions or isolates.
(A) Confirmed and suspected human cases of the following
diseases/infections are reportable: acquired immune deficiency syndrome
(AIDS); amebiasis; amebic meningitis and encephalitis; anaplasmosis;
anthrax; arboviral infections caused by California serogroup virus,
Eastern equine encephalitis (EEE) virus, Powassan virus, St. Louis
encephalitis (SLE) virus, Western equine encephalitis (WEE) virus,
and West Nile (WN) virus; babesiosis; botulism-adult and infant; brucellosis;
campylobacteriosis; Chagas' disease; chancroid; chickenpox (varicella); Chlamydia trachomatis infection; Creutzfeldt-Jakob
disease (CJD); cryptosporidiosis; cyclosporiasis; dengue; diphtheria;
ehrlichiosis; shiga-toxin producing Escherichia
coli infection; gonorrhea; Hansen's disease (leprosy); Haemophilus influenzae type b infection,
invasive; hantavirus infection; hemolytic uremic syndrome (HUS); hepatitis
A, B, C, and E, (acute); hepatitis B, (acute and chronic) identified
prenatally or at delivery; perinatal hepatitis B infection; human
immunodeficiency virus (HIV) infection; influenza-associated pediatric
mortality; legionellosis; leishmaniasis; listeriosis; Lyme disease;
malaria; measles (rubeola); meningococcal infection, invasive; novel
influenza; mumps; pertussis; plague; poliomyelitis, acute paralytic;
poliovirus infection, non-paralytic; Q fever; rabies; relapsing fever;
rubella (including congenital); salmonellosis, including typhoid fever;
severe acute respiratory syndrome (SARS) as defined by the United
States Centers for Disease Control and Prevention; shigellosis; smallpox;
spotted fever group rickettsioses (such as Rocky Mountain spotted
fever); streptococcal disease: invasive group A, invasive group B,
or invasive Streptococcus pneumoniae; syphilis; Taenia solium and undifferentiated Taenia infections, including cysticercosis;
tetanus; trichinosis; tuberculosis; tularemia; typhus; Vibrio infection, including cholera (specify
species); viral hemorrhagic fevers; yellow fever; yersiniosis; and
vancomycin-intermediate resistant Staphylococcus
aureus (VISA), and vancomycin-resistant Staphylococcus
aureus (VRSA).
(B) In addition to individual case reports, any outbreak,
exotic disease, or unusual group expression of disease that may be
of public health concern should be reported by the most expeditious
means.
(3) Minimal reportable information requirements. The
minimal information that shall be reported for each disease is as
follows:
(A) AIDS, chancroid, Chlamydia
trachomatis infection, gonorrhea, HIV infection, and syphilis
shall be reported in accordance with §§97.132 - 97.134 of
this title (relating to Sexually Transmitted Diseases Including Acquired
Immune Deficiency Syndrome (AIDS) and Human Immunodeficiency Virus
(HIV));
(B) for tuberculosis disease - complete name, date
of birth, physical address and county of residence, information on
which diagnosis was based or suspected. In addition, if known, radiographic
or diagnostic imaging results and date(s); all information necessary
to complete the most recent versions of forms TB 400 A & B (Report
of Case and Patient Services), TB 340 (Report of Contacts) and TB
341 (Continuation of Report of Contacts); laboratory results used
to guide prescribing, monitoring or modifying antibiotic treatment
regimens for tuberculosis to include, but not limited to, liver function
studies, renal function studies, and serum drug levels; pathology
reports related to diagnostic evaluations of tuberculosis; reports
of imaging or radiographic studies; records of hospital or outpatient
care to include, but not limited to, histories and physical examinations,
discharge summaries and progress notes; records of medication administration
to include, but not limited to, directly observed therapy (DOT) records,
and drug toxicity and monitoring records; a listing of other patient
medications to evaluate the potential for drug-drug interactions;
and copies of court documents related to court ordered management
of tuberculosis.
(C) for contacts to a known case of tuberculosis -
complete name; date of birth; physical address; county of residence;
and all information necessary to complete the most recent versions
of forms TB 400 A & B (Report of Case and Patient Services), TB
340 (Report of Contacts), and TB 341 (Continuation of Report of Contacts);
(D) for other persons identified with latent TB infection
- complete name; date of birth; physical address and county of residence;
and diagnostic information;
(E) for hepatitis B (chronic and acute) identified
prenatally or at delivery - mother's name, address, telephone number,
age, date of birth, sex, race and ethnicity, preferred language, hepatitis
B laboratory test results; estimated delivery date or date and time
of birth; name and phone number of delivery hospital or planned delivery
hospital; name of infant; name, phone number, and address of medical
provider for infant; date, time, formulation, dose, manufacturer,
and lot number of hepatitis B vaccine and hepatitis B immune globulin
administered to infant;
(F) for hepatitis A, B, C, and E - name, address, telephone
number, age, date of birth, sex, race and ethnicity, disease, diagnostic
indicators (diagnostic lab results, including all positive and negative
hepatitis panel results, liver function tests, and symptoms), date
of onset, pregnancy status, and physician name, address, and telephone
number;
(G) for perinatal hepatitis B - name of infant; date
of birth; sex; race; ethnicity; name, phone number and address of
medical provider for infant; date, time, formulation, dose, manufacturer,
and lot number of hepatitis B vaccine and hepatitis B immune globulin
administered to infant, hepatitis B laboratory test results;
(H) for chickenpox - name, date of birth, sex, race
and ethnicity, address, date of onset, and varicella vaccination history;
(I) for VISA; and VRSA - name, address, telephone number,
age, date of birth, sex, race and ethnicity, disease, diagnostic indicators
(diagnostic lab results, anatomic site of culture, and clinical indicators),
date of onset, and physician name, address, and telephone number;
(J) for Hansen's disease - name; date of birth; sex;
race and ethnicity; social security number; disease type; place of
birth; address; telephone number; date entered Texas; date entered
U.S.; education/employment; insurance status; location and inclusive
dates of residence outside U.S.; date of onset and history prior to
diagnosis; date of initial biopsy and result; date initial drugs prescribed
and name of drugs; name, date of birth and relationship of household
contacts; and name, address, and telephone number of physician;
(K) for novel influenza investigations occurring during
an influenza pandemic--minimal reportable information on individual
cases, a subset of cases or aggregate data will be specified by the
department;
(L) for all other notifiable conditions listed in paragraph
(2)(A) of this subsection - name, address, telephone number, age,
date of birth, sex, race and ethnicity, disease, diagnostic indicators
(diagnostic lab results and specimen source, and clinical indicators),
date of onset, and physician name, address, and telephone number;
and
(M) other information may be required as part of an
investigation in accordance with Texas Health and Safety Code, §81.061.
(4) Diseases requiring submission of cultures. For
all anthrax (Bacillus anthracis), botulism-adult
and infant (Clostridium botulinum), brucellosis (Brucella species), E.coli
0157:H7, isolates or specimens from cases where Shiga-toxin
activity is demonstrated, Listeria monocytogenes,
meningococcal infection, invasive (Neisseria
meningitides from normally sterile sites), plague (Yersinia pestis), tuberculosis (Mycobacterium tuberculosis complex), tularemia (Francisella tularensis), all Staphylococcus aureus with a vancomycin
MIC greater than 2 µg/mL, and Vibrio species
- pure cultures shall be submitted accompanied by a current department
Specimen Submission Form.
(5) Laboratory reports. Reports from laboratories shall
include name, patient identification number, address, telephone number,
age, date of birth, sex, race and ethnicity, specimen submitter name,
address, and phone number, specimen type, date specimen collected,
disease test and test result, normal test range, date of test report,
and physician name and telephone number.
(b) Animals.
(1) Clinically diagnosed or laboratory-confirmed animal
cases of the following diseases are reportable: anthrax, arboviral
encephalitis, Chagas' disease, Mycobacterium
tuberculosis infection in animals other than those housed in
research facilities, plague, and psittacosis. Also, all non-negative
rabies tests performed on animals from Texas at laboratories located
outside of Texas shall be reported; all non-negative rabies tests
performed in Texas will be reported by the laboratory conducting the
testing. In addition to individual case reports, any outbreak, exotic
disease, or unusual group expression of disease which may be of public
health concern should be reported by the most expeditious means.
(2) The minimal information that shall be reported
for each disease includes species and number of animals affected,
disease or condition, name and phone number of the veterinarian or
other person in attendance, and the animal(s) owner's name, address,
and phone number. Other information may be required as part of an
investigation in accordance with Texas Health and Safety Code, §81.061.
|
